NEW YORK (GenomeWeb News) – Shares in Invitrogen were down approximately 9.8 percent, or $6.10, at $56.23 in mid-afternoon trading today after the company reported lower-than-expected revenues for the second quarter, and lowered its financial guidance.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.